For more than three decades, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center researchers have pursued an ambitious idea: that vaccines could train the immune system to recognize and fight cancer. Now, a landmark phase 3 clinical trial of a personalized melanoma vaccine shows that this approach can improve outcomes for patients. Johns Hopkins Kimmel Cancer Center was among the clinical centers that participated in the multicenter study.